GlycoMimetics announces GMI-1687 trial met primary, secondary endpoints

GlycoMimetics announced initial safety, tolerability, and pharmacokinetic results from a Phase 1a study of GMI-1687 in healthy volunteers. This double-blind, single-center, randomized, placebo-controlled, sequential, single ascending dose Phase 1a trial in healthy adult volunteers enrolled 40 subjects. Eligible subjects received a single subcutaneous injection of GMI-1687 or placebo. Five dose levels were evaluated, including 3.3, 10, 20, 40, and 80 mg. The study met its primary and secondary endpoints of safety/tolerability and pharmacokinetics. There were no observed dose limiting toxicities or safety signals. Subcutaneous dosing achieved target therapeutic plasma concentration and linear pharmacokinetics with rapid renal clearance across all dosing levels. Analysis of data is ongoing with full results expected to be presented at an upcoming medical conference.